Medical Staff Quality Improvement Award, University of Colorado Hospital
(2021)
John Quale Travel Fellowship, Bladder Cancer Advocacy Network
(2017)
Outstanding Laparoendoscopic Resident Award, Society for Laparoendoscopic Surgeons
(2017)
Research Interests
Bladder Cancer
Teaching
Associate Professor
(2018)
School of Medicine,
Surgery
Bladder Cancer, Urologic Oncology
Publications
Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol. 2022 Oct;208(4):886-895. PubMed PMID: 36082549
Kukreja JB, Schroeck FR, Lotan Y, Gore JL, Ullman R, Lipman RR, Murray MBB, Chisolm S, Smith AB. Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. Urol Oncol. 2022 Jan;40(1):9.e19-9.e27. PubMed PMID: 34162499
Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus. 2021 Jan;7(1):71-77. PubMed PMID: 31076357
Pessoa RR, Maroni P, Kukreja J, Kim SP. Comparative effectiveness of robotic and open radical prostatectomy. Transl Androl Urol. 2021 May;10(5):2158-2170. PubMed PMID: 34159098
Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol. 2021 Dec;39(12):832.e9-832.e15. PubMed PMID: 33820697
Kukreja JB, Li R, Narayan VM, Lim A, Seif M, Wang X, Kamat A, Dinney C, Navai N. Oncologic Equipoise Between Robotic and Open Radical Cystectomy. J Endourol. 2021 Aug;35(8):1168-1176. PubMed PMID: 33619985
Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP, Shah JB, Feeley TW, Navai N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. 2021 Apr;39(4):237.e1-237.e5. PubMed PMID: 33308972
Rodriguez-Homs M, Baack Kukreja J. Bladder cancer biomarkers: Past and future directions. BJUI Compass. 2021 Jan;2(1):7-8. PubMed PMID: 35474658
Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP, Shah JB, Feeley TW, Navai N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. 2021 Apr;39(4):237.e1-237.e5. PubMed PMID: 33308972
Rodrigues Pessoa R, Morrison JC, Konety B, Gershman B, Maroni P, Kukreja JB, Cost N, Flaig T, Kessler E, Sharma P, Kim SP. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Urol Oncol. 2021 Dec;39(12):832.e9-832.e15. PubMed PMID: 33820697
Pessoa RR, Maroni P, Kukreja J, Kim SP. Comparative effectiveness of robotic and open radical prostatectomy. Transl Androl Urol. 2021 May;10(5):2158-2170. PubMed PMID: 34159098
Kukreja JB, Schroeck FR, Lotan Y, Gore JL, Ullman R, Lipman RR, Murray MBB, Chisolm S, Smith AB. Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. Urol Oncol. 2021 Jun 20. [Epub ahead of print] PubMed PMID: 34162499
Reichard CA, Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus. 2021 Jan;7(1):71-77. PubMed PMID: 31076357
Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):172-178. PubMed PMID: 31501508
Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CPN, Navai N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2020 Jan 15;6(1):88-94. PubMed PMID: 30033071
AUA Core Curriculum on Urethral Cancer
Rodriguez-Homs M, Baack Kukreja J. Biomarkers cancer biomarkers, past and future directions. Jan 2021. BJUI Compass. https://doi.org/10.1002/bco2.61.
Pessoa-Rodriguez R, Boxley P, Kukreja J. Comparative effectiveness of Robotic and Open Radical Cystectomy. American Medical J. 2020. http://dx.doi.org/10.21037/amj-20-81
Urkmez A, Pessoa-Rodriguez R, Kukreja N, Kukreja JEB. Enhanced Recovery after Surgery and Urology applications in 2020. Accepted to BJUI Compass. Open access 2020. DOI: 10.1002/bco2.9
Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CPN, Navai N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2020 Jan 15;6(1):88-94. PubMed PMID: 30033071
Baack Kukreja J, Bathala TK, Reichard CA, Troncoso P, Delacroix S, Davies B, Eggener S, Smaldone M, Minhaj Siddiqui M, Tollefson M, Chapin BF. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):172-178. PubMed PMID: 31501508
Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol. 2020 Apr;38(4):247-254. PubMed PMID: 31953001
Baack Kukreja J, Seif MA, Lozano M, Wang X, Hwang H, Kamat AM, Dinney CPN, Navai N. Preoperative immunonutrition in patients treated with radical cystecotmy, results from a phase 1, “Oral Immunonutrition to Enhance Recovery after Surgery” feasibility trial. AUA, Chicago, IL May 2019. (presented by Baack Kukreja)
Baack Kukreja J, Navai N, Li J, Meng Q, Seif MA, Hwang H, Kamat AM, Westney OL, Dinney CPN. Testosterone levels and perioperative outcomes in patients treated with radical cystectomy, results from the “Oral Immunonutrition to Enhance Recovery after Surgery” trial. AUA, Chicago, IL May 2019. Podium presentation. (presented by Baack Kukreja)
Baack Kukreja J, Seif MA, Kamat AM, Dinney CPN, Navai N. Surgical Quality of Radical Cystectomy. GU ASCO, San Francisco, CA February 2019. (presented by Baack Kukreja)
Baack Kukreja JE, Lloyd G.L. Robotically Assisted Radical Cystectomy. In: Best S., Nakada S. (eds) Minimally Invasive Urology. Springer, New York, NY, 2019.
Baack Kukreja J. Venous Thromboembolism Prophylaxis in Urologic Surgery. AUA Update Series.
Reichard CA, Baack Kukreja J, Gregg JR, Bathala TK, Achim MF, Wang X, Davis JW, Nguyen QN, Chapin BF. Prediction of Organ-confined Disease in High- and Very-high-risk Prostate Cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design. Eur Urol Focus. May 2019;S2405-4569(19)30132-4. Epub ahead of print. PMID: 31076357
Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, Conzalez GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol Mar 2019. PMID: 30864005.
Kukreja JB, Thompson IM Jr, Chapin BF. Organizing a clinical trial for the new investigator. Urol Oncol. 2019 May;37(5):336-339. PMID 2939593.
Truong M, Baack Kukreja JE, Rais-Bahrami S, Barashi NS, Wang B, Nuffer Z, Park JH, Lam K, Frye TP, Nix JW, Thomas JV, Feng C, Chapin BF, Davis JW, Hollenberg G, Oto A, Eggener SE, Joseph JV, Weinberg E, Messing EM. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 May;2(3):257-264. PubMed PMID: 31200839
Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Dec;37(12):2691-2698. PubMed PMID: 30864005
Berrondo C, Feng C, Kukreja JB, Messing EM, Joseph JV. Antibiotic prophylaxis at the time of catheter removal after radical prostatectomy: A prospective randomized clinical trial. Urol Oncol. 2018 Dec 14. [Epub ahead of print] PubMed PMID: 30558984
Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D. A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer. 2018 Oct 3;4(Suppl 1):S1-S43. PubMed PMID: 30443561
Kukreja JB, Metcalfe MJ, Qiao W, Kamat AM, Dinney CPN, Navai N. Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. Eur Urol Focus. 2018 Jul 19. [Epub ahead of print] PubMed PMID: 30033071
Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov. 2018 Jun;25(3):242-250. PubMed PMID: 29557251
Li R, Metcalfe M, Kukreja J, Navai N. Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. Bladder Cancer. 2018 Jan 20;4(1):31-40. PubMed PMID: 29430505
Kukreja JB, Thompson IM Jr, Chapin BF. Organizing a clinical trial for the new investigator. Urol Oncol. 2018 Feb 1. [Epub ahead of print] PubMed PMID: 29395953
Li R, Baack Kukreja JE, Kamat AM. Secondary Tumors After Urinary Diversion. Urol Clin North Am. 2018 Feb;45(1):91-99. PubMed PMID: 29169454
Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 Sep;4(5):720-724. PubMed PMID: 28753837
Baack Kukreja J, Kamat AM. Strategies to minimize readmission rates following major urologic surgery. Ther Adv Urol. 2017 Oct;9(5):111-119. PubMed PMID: 28588648
Truong M, Liang L, Kukreja J, O'Brien J, Jean-Gilles J, Messing E. Cautery artifact understages urothelial cancer at initial transurethral resection of large bladder tumours. Can Urol Assoc J. 2017 May;11(5):E203-E206. PubMed PMID: 28503235
Baack Kukreja JE, Kiernan M, Schempp B, Siebert A, Hontar A, Nelson B, Dolan J, Noyes K, Dozier A, Ghazi A, Rashid HH, Wu G, Messing EM. Quality Improvement in Cystectomy Care with Enhanced Recovery (QUICCER) study. BJU Int. 2017 Jan;119(1):38-49. PubMed PMID: 27128851
Broughton BL, Baron B, Kiernan M, Baack-Kukreja J, LaFaro VE, Larmon R, Rust K, Schempp BA, Yovanovich J. Cystectomy-Enhanced Recovery Program: Nursing Implications. Urol Nurs. 2017 Jan-Feb;37(1):9-14. PubMed PMID: 29240359
Kukreja JB, Shah JB. Advances in surgical management of muscle invasive bladder cancer. Indian J Urol. 2017 Apr-Jun;33(2):106-110. PubMed PMID: 28469297
Li R, Petros FG, Kukreja JB, Williams SB, Davis JW. Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investig Clin Urol. 2016 Dec;57(Suppl 2):S155-S164. PubMed PMID: 27995219
Noyes K, Baack-Kukreja J, Messing EM, Schoeniger L, Galka E, Pan W, Xueya C, Fleming FJ, Monson JR, Mohile SG, Francone T. Surgical readmissions: results of integrating pre-, peri- and postsurgical care. Nurs Open. 2016 Jul;3(3):168-178. PubMed PMID: 27708827
Baack Kukreja JE, Messing EM, Shah JB. Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists. Urol Oncol. 2016 Mar;34(3):120.e17-21. PubMed PMID: 26585947
Danna BJ, Wood EL, Baack Kukreja JE, Shah JB. The Future of Enhanced Recovery for Radical Cystectomy: Current Evidence, Barriers to Adoption, and the Next Steps. Urology. 2016 Oct;96:62-68. PubMed PMID: 27164287
Kukreja JE, Levey HR, Scosyrev E, Kiernan M, Berrondo C, McNamee C, Wu G, Joseph JV, Ghazi A, Rashid H, Dozier A, Messing EM. Effectiveness and safety of extended-duration prophylaxis for venous thromboembolism in major urologic oncology surgery. Urol Oncol. 2015 Sep;33(9):387.e7-16. PubMed PMID: 25637953
Baack Kukreja JE, Scosyrev E, Brasacchio RA, Toy EP, Messing EM, Wu G. Bladder cancer incidence and mortality in patients treated with radiation for uterine cancer. BJU Int. 2014 Dec;114(6):844-51. PubMed PMID: 26010047
Lee EK, Baack J, Duchene DA. Survey of practicing urologists: robotic versus open radical prostatectomy. Can J Urol. 2010 Apr;17(2):5094-8. PubMed PMID: 20398448
Lee EK, Baack J, Penn H, Bromfield CT, Duchene DA, Thrasher JB, Holzbeierlein JM. Active surveillance for prostate cancer in a veteran population. Can J Urol. 2010 Dec;17(6):5429-35. PubMed PMID: 21172105
Clinical Interests
Dr. Kukreja particular interest in the treatment of urologic cancers and focuses on bladder cancer for research. She believes in providing the most advanced therapies and technology and care for patients with urologic cancers. She has a special interest in perioperative care. She offers the following procedures robotic bladder (cystectomy/cystoprostatectomy) also known as a robotic cystectomy and urinary diversion creation (Ileal conduit, Indiana Pouch and Neobladder. She also offers robotic removal of: adrenal glands, prostate (prostatectomy), kidney (nephrectomy), partial kidney (partial nephrectomy/nephron sparing surgery), minimally invasive surgery, retroperitoneal lymph node dissection, inguinal lymph node removal, ureteral removal (partial ureterectomy).
Care Philosophy
Dr. Kukreja believes in providing the best care for urological cancer patients. This includes a multidisciplinary approach as well as the most advanced technology. Working with patients in developing a treatment plan is extremely important in the treatment of urologic cancers. Patients with urologic cancers often have unique needs and these must be recognized. She hopes that through the latest developments in surgery and cancer care we can provide the best urologic cancer care. Dr. Kukreja performs about 100 robot assisted bladder removal cases per year (radical cystectomies). Dr. Kukreja believes that having a physician that performs many of the same procedures per year improves outcomes and decreases complications. Dr. Kukreja performs the urinary diversions inside of the body with the robot and without making a larger incision.
Personal Interests
I am very passionate about all urologic cancers, specifically bladder cancer. I have a particular interest in perioperative care for all cancer patients.
Public Speaking Yes
I speak often about bladder cancer, surgery for bladder cancer and perioperative care for bladder cancer.
General Information
Medical Schools:
MD, University of Missouri-Kansas City School of Medicine
(2010)
Graduate Schools:
MPH, University of Rochester
(2014)
Undergraduate Schools:
BA, University of Missouri–Kansas City (MO)
(2009)
Residency Programs:
University of Rochester Program, Chief Resident, Urology (2016)
Fellowships:
University of Texas at Houston/M D Anderson Cancer Center Program, Urologic Oncology
(2018)